Radiopharm Theranostics (RADX) Competitors $5.33 -0.23 (-4.14%) As of 10/24/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsOwnershipSEC FilingsShort InterestTrendsBuy This Stock RADX vs. EPRX, GNFT, SGMO, BHST, CHRS, GNLX, MXCT, IPHA, PRE, and NKTXShould you be buying Radiopharm Theranostics stock or one of its competitors? The main competitors of Radiopharm Theranostics include Eupraxia Pharmaceuticals (EPRX), GENFIT (GNFT), Sangamo Therapeutics (SGMO), BioHarvest Sciences (BHST), Coherus Oncology (CHRS), Genelux (GNLX), MaxCyte (MXCT), Innate Pharma (IPHA), Prenetics Global (PRE), and Nkarta (NKTX). These companies are all part of the "med - biomed/gene" industry. Radiopharm Theranostics vs. Its Competitors Eupraxia Pharmaceuticals GENFIT Sangamo Therapeutics BioHarvest Sciences Coherus Oncology Genelux MaxCyte Innate Pharma Prenetics Global Nkarta Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Which has higher valuation and earnings, EPRX or RADX? Radiopharm Theranostics has higher revenue and earnings than Eupraxia Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.85-6.44Radiopharm Theranostics$2.35M17.87-$24.83MN/AN/A Do analysts prefer EPRX or RADX? Eupraxia Pharmaceuticals presently has a consensus price target of $11.00, indicating a potential upside of 101.10%. Radiopharm Theranostics has a consensus price target of $15.00, indicating a potential upside of 181.43%. Given Radiopharm Theranostics' stronger consensus rating and higher probable upside, analysts clearly believe Radiopharm Theranostics is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86Radiopharm Theranostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00 Does the media favor EPRX or RADX? In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Eupraxia Pharmaceuticals and 1 mentions for Radiopharm Theranostics. Eupraxia Pharmaceuticals' average media sentiment score of 1.93 beat Radiopharm Theranostics' score of 1.89 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eupraxia Pharmaceuticals Very Positive Radiopharm Theranostics Very Positive Is EPRX or RADX more profitable? Radiopharm Theranostics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -626.84% -118.31% Radiopharm Theranostics N/A N/A N/A SummaryRadiopharm Theranostics beats Eupraxia Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Get Radiopharm Theranostics News Delivered to You Automatically Sign up to receive the latest news and ratings for RADX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RADX vs. The Competition Export to ExcelMetricRadiopharm TheranosticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.83M$3.43B$6.23B$10.66BDividend YieldN/A2.27%5.71%4.82%P/E RatioN/A24.2730.2930.24Price / Sales17.87494.27591.44133.15Price / CashN/A45.5737.0161.44Price / Book1.5110.4012.046.60Net Income-$24.83M-$52.62M$3.32B$276.82M7 Day Performance-25.04%2.09%1.89%2.58%1 Month Performance-7.30%12.32%7.68%3.76%1 Year PerformanceN/A14.12%56.01%33.84% Radiopharm Theranostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RADXRadiopharm Theranostics3.3694 of 5 stars$5.33-4.1%$15.00+181.4%N/A$43.83M$2.35M0.00N/APositive NewsEPRXEupraxia Pharmaceuticals2.8871 of 5 stars$5.87-0.7%$11.00+87.4%+119.7%$212.53MN/A-6.9129Short Interest ↑GNFTGENFIT2.2327 of 5 stars$4.16-1.9%$7.00+68.3%-23.3%$211.92M$76.77M0.00120Gap DownSGMOSangamo Therapeutics2.2648 of 5 stars$0.64-6.5%$4.50+597.8%-57.5%$208.18M$57.80M-2.22480Positive NewsBHSTBioHarvest Sciences2.5513 of 5 stars$11.50-9.1%$13.67+18.8%N/A$207.70M$25.19M-16.43N/ANews CoverageAnalyst ForecastShort Interest ↑Gap UpCHRSCoherus Oncology4.2051 of 5 stars$1.71-3.9%$4.51+163.9%+107.8%$206.88M$266.96M1.10330News CoverageAnalyst ForecastGNLXGenelux1.3839 of 5 stars$5.36-1.5%$20.33+279.4%+210.3%$205.49M$10K-6.2310Analyst ForecastGap UpMXCTMaxCyte3.9685 of 5 stars$1.77-3.3%$7.00+295.5%-57.1%$195.09M$38.63M-4.1280IPHAInnate Pharma2.8197 of 5 stars$2.14+1.4%$6.50+203.7%+19.0%$194.51M$21.77M0.00220PREPrenetics Global1.1524 of 5 stars$15.86+6.9%$9.00-43.3%+255.8%$192.70M$30.62M-3.971Positive NewsNKTXNkarta2.7185 of 5 stars$2.49-5.3%$13.50+442.2%-33.8%$186.79MN/A-1.68140News CoveragePositive NewsAnalyst Upgrade Related Companies and Tools Related Companies EPRX Competitors GNFT Competitors SGMO Competitors BHST Competitors CHRS Competitors GNLX Competitors MXCT Competitors IPHA Competitors PRE Competitors NKTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RADX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Radiopharm Theranostics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Radiopharm Theranostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
